Sherlock Biosciences, Inc., a biotechnology company, develops molecular diagnostics solutions. It offers SHERLOCK, a CRISPR-based method to detect and quantify specific genetic sequences, and INSPECTR, a synthetic biology-based molecular diagnostics platform. The company offers its products in the areas of precision oncology, infection identification, food safety, at-home tests, and disease detection. The company was incorporated in 2018 and is based in Cambridge, Massachusetts.
Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.
Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System.
Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools. The company focuses on developing innovative DNA synthesis solutions, including oligonucleotides, genes, pathways, and genomes. Its flagship product, the SYNTAX benchtop DNA printer, utilizes groundbreaking enzymatic technology, allowing laboratories to produce their own synthetic oligonucleotides. This capability enhances workflow control and accelerates access to results, thereby facilitating advancements in life sciences and human health.
RedShiftBio provides an infrared technology with advanced data analytics to facilitate better, faster decision making in biopharmaceutical development from discovery to market via the direct measurement of previously undetectable change in protein structural attributes critical to drug product efficacy and quality. It has developed a Microfluidic Modulation Spectroscopy (MMS) platform in response to a customer’s request for a better solution, and rather than repurpose outdated tools and methods designed originally for other applications. They started a new and developed MMS from the ground up specifically with the protein scientist in mind.
The company was founded in 2005 and is headquartered in Burlington, Massachusetts.
Walking Fish Therapeutics is developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies.
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.
NanoCellect Biomedical, Inc. develops innovative flow cytometry and cell sorting technology aimed at enhancing the capabilities of life science researchers in cellular analysis, molecular diagnostics, and personalized medicine. Founded in 2009 and based in San Diego, California, the company offers the WOLF Cell Sorter, which utilizes a closed fluid-path microfluidic cartridge to facilitate cell sorting while minimizing biohazard risks and shear stress commonly associated with traditional methods. By making flow cytometry more affordable and accessible, NanoCellect aims to support biomedical researchers in analyzing and isolating cells efficiently, thereby promoting significant advancements in drug discovery and diagnostics. The company's technology is designed to provide rapid, objective, and quantitative data on individual cells, empowering scientists to conduct essential research with greater ease and precision.
LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, NY, with tests covering general wellness, sexual health, women's health and men's health, and is available nationwide, as well as in Canada and Europe.
NanoCellect Biomedical, Inc. develops innovative flow cytometry and cell sorting technology aimed at enhancing the capabilities of life science researchers in cellular analysis, molecular diagnostics, and personalized medicine. Founded in 2009 and based in San Diego, California, the company offers the WOLF Cell Sorter, which utilizes a closed fluid-path microfluidic cartridge to facilitate cell sorting while minimizing biohazard risks and shear stress commonly associated with traditional methods. By making flow cytometry more affordable and accessible, NanoCellect aims to support biomedical researchers in analyzing and isolating cells efficiently, thereby promoting significant advancements in drug discovery and diagnostics. The company's technology is designed to provide rapid, objective, and quantitative data on individual cells, empowering scientists to conduct essential research with greater ease and precision.
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that specializes in early cancer detection through non-invasive blood tests. Founded in 2018, the company utilizes advanced artificial intelligence and genome sequencing technologies to identify unique patterns of DNA fragmentation in patients' blood, enabling the detection of cancer at its most treatable stage. By focusing on precision diagnostics, Delfi Diagnostics aims to improve patient outcomes and contribute to the evolving landscape of cancer care.
Rebus Biosystems, Inc. is a life science technology company based in Santa Clara, California, specializing in spatial omics tools. The company has developed the Rebus Esper, an automated spatial omics platform that integrates advanced imaging, on-system chemistry, and user-friendly software to deliver quantitative data at subcellular resolution. This platform allows researchers to analyze biological molecules across large tissue sections while preserving spatial context. Rebus Biosystems focuses on automating microfluidics for sequential labeling of expressed transcripts, enabling high-resolution imaging that supports applications in pharmaceutical research, particularly in visualizing gene expression profiles in human brain tissues. Founded in 2006 and formerly known as Optical Biosystems, Rebus Biosystems continues to innovate in the realm of spatial omics to enhance research capabilities.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools. The company focuses on developing innovative DNA synthesis solutions, including oligonucleotides, genes, pathways, and genomes. Its flagship product, the SYNTAX benchtop DNA printer, utilizes groundbreaking enzymatic technology, allowing laboratories to produce their own synthetic oligonucleotides. This capability enhances workflow control and accelerates access to results, thereby facilitating advancements in life sciences and human health.
Encoded Therapeutics, Inc. is a biotechnology company focused on developing precision gene therapies for severe genetic disorders. The company's innovative platform identifies sequences within the human genome that regulate gene expression through advanced screening and computational methods. Its therapy pipeline targets a variety of genetic and acquired disorders across multiple disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and headquartered in South San Francisco, California, Encoded Therapeutics aims to enhance treatment options available to medical practitioners, ultimately improving patient outcomes and quality of life.
Pattern Bioscience is a privately held in vitro diagnostics company founded in 2016 to help combat the problem of antibiotic resistance. Pattern is developing a next-generation clinical microbiology platform based on its patented phenotypic single-cell technology that can rapidly identify pathogens and determine their antibiotic response without the need for traditional time-consuming culture steps. Pattern’s Digital CultureTM technology relies on functional endpoints that encompass all possible resistance mechanisms, resulting in a more comprehensive and reliable diagnosis compared to rapid genotypic tests. The platform will deliver more reliable diagnoses days faster than the current standard of care.
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, NY, with tests covering general wellness, sexual health, women's health and men's health, and is available nationwide, as well as in Canada and Europe.
Actym is a biotechnology company that focuses on developing an immuno-oncology platform. It specializes in the fields of medical device, manufacturing, and distribution. It focuses on a novel tumor-targeting, systemically-delivered STING pathway agonist that demonstrates robust anti-tumor.
It was founded in 2017 and headquartered in San Francisco, California.
Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.
Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System.
Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.
Fluent BioSciences is a privately funded life science company focused on developing high-sensitivity molecular analytical products. Utilizing proprietary instrument-free micro-self-assembly technology, the company enables the analysis of extremely low molecular and cellular sample inputs. Its platform facilitates the instantaneous self-assembly of individual cells or molecules into millions of uniform partitions, allowing for sensitive and unbiased preparation of proteins and nucleic acids for sequencing applications. This innovative approach provides researchers in the biotechnology sector with enhanced capabilities for single-cell analysis, broadening their access to advanced analytical techniques.
Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases.
Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that specializes in early cancer detection through non-invasive blood tests. Founded in 2018, the company utilizes advanced artificial intelligence and genome sequencing technologies to identify unique patterns of DNA fragmentation in patients' blood, enabling the detection of cancer at its most treatable stage. By focusing on precision diagnostics, Delfi Diagnostics aims to improve patient outcomes and contribute to the evolving landscape of cancer care.
At Cradle Genomics, their mission is to provide knowledge that helps every pregnancy. They're dedicated to the transformation of non-invasive prenatal testing (NIPT) by offering the most comprehensive fetal genetic analysis and pregnancy health screening solutions at the earliest stages of pregnancy.
Cradle Genomics is newly formed with their headquarters based in San Diego and additional R&D operations located in Detroit. Cradle tests are based on the genetic analysis of fetal cells that are quickly collected during a first trimester visit with no risk to the mother or developing fetus.
Encoded Therapeutics, Inc. is a biotechnology company focused on developing precision gene therapies for severe genetic disorders. The company's innovative platform identifies sequences within the human genome that regulate gene expression through advanced screening and computational methods. Its therapy pipeline targets a variety of genetic and acquired disorders across multiple disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and headquartered in South San Francisco, California, Encoded Therapeutics aims to enhance treatment options available to medical practitioners, ultimately improving patient outcomes and quality of life.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools. The company focuses on developing innovative DNA synthesis solutions, including oligonucleotides, genes, pathways, and genomes. Its flagship product, the SYNTAX benchtop DNA printer, utilizes groundbreaking enzymatic technology, allowing laboratories to produce their own synthetic oligonucleotides. This capability enhances workflow control and accelerates access to results, thereby facilitating advancements in life sciences and human health.
LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.
LunaPBC, Inc. operates a community-owned platform focused on health and DNA research. The company offers LunaDNA, a database that facilitates the sharing of health and genetic data for medical research. This platform supports health research initiatives by both non-profit and for-profit organizations, contributing to medical discoveries. LunaPBC operates as a Public Benefit Corporation, emphasizing community welfare by allowing individuals to share their health data, which in turn drives research and innovation. Additionally, members of the platform have the opportunity to share in the earnings derived from medical advancements, promoting a sense of shared ownership and benefit within the community. Founded in 2017 and based in San Diego, California, LunaPBC aims to advance genomic and medical research while prioritizing the interests of its contributors.
Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.
Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System.
Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.
Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases.
Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.
Cernostics is a life science company developing new molecular diagnostic tests for the fight against cancer. Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple cell types, not merely tumor cells.
Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics.
Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.
NanoCellect Biomedical, Inc. develops innovative flow cytometry and cell sorting technology aimed at enhancing the capabilities of life science researchers in cellular analysis, molecular diagnostics, and personalized medicine. Founded in 2009 and based in San Diego, California, the company offers the WOLF Cell Sorter, which utilizes a closed fluid-path microfluidic cartridge to facilitate cell sorting while minimizing biohazard risks and shear stress commonly associated with traditional methods. By making flow cytometry more affordable and accessible, NanoCellect aims to support biomedical researchers in analyzing and isolating cells efficiently, thereby promoting significant advancements in drug discovery and diagnostics. The company's technology is designed to provide rapid, objective, and quantitative data on individual cells, empowering scientists to conduct essential research with greater ease and precision.
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.
LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.
NanoCellect Biomedical, Inc. develops innovative flow cytometry and cell sorting technology aimed at enhancing the capabilities of life science researchers in cellular analysis, molecular diagnostics, and personalized medicine. Founded in 2009 and based in San Diego, California, the company offers the WOLF Cell Sorter, which utilizes a closed fluid-path microfluidic cartridge to facilitate cell sorting while minimizing biohazard risks and shear stress commonly associated with traditional methods. By making flow cytometry more affordable and accessible, NanoCellect aims to support biomedical researchers in analyzing and isolating cells efficiently, thereby promoting significant advancements in drug discovery and diagnostics. The company's technology is designed to provide rapid, objective, and quantitative data on individual cells, empowering scientists to conduct essential research with greater ease and precision.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools. The company focuses on developing innovative DNA synthesis solutions, including oligonucleotides, genes, pathways, and genomes. Its flagship product, the SYNTAX benchtop DNA printer, utilizes groundbreaking enzymatic technology, allowing laboratories to produce their own synthetic oligonucleotides. This capability enhances workflow control and accelerates access to results, thereby facilitating advancements in life sciences and human health.
Serimmune Inc., a biotechnology company, develops diagnostics and therapeutics for autoimmune diseases. It offers serum epitope repertoire analysis (SERA) technology platform that applies bacterial display peptide libraries, sequencing, machine learning, and custom bioinformatics to reveal the diverse antigens stimulating immunity. It maps the distinct antibodies within a repertoire to antigens associated with infections, allergens, micro biome organisms, autoimmune diseases, and cancers. The company was founded in 2014 and is based in Goleta, California.
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.
Human Longevity (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. Its business areas include the HLI Health Nucleus, a genomic powered clinical research center that uses whole-genome sequence analysis, advanced clinical imaging, and innovative machine learning, along with curated personal health information to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. It was founded in 2013 and is headquartered in San Diego, California.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by the real-world impact of CRISPR technology. They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.
Biota Technology, Inc. applies deoxyribonucleic acid (DNA) sequencing and data science to explore the earth’s subsurface. It offers DNA data services for production profiling, sweet spot identification, and reservoir connectivity. The company provides actionable insights to the oil industry for maximizing reservoir production and reducing environmental impact. Biota Technology, Inc. was incorporated in 2012 and is based in San Diego, California.
Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.
23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.